Coherus BioSciences, Inc. (CHRS)
| Market Cap | 370.84M |
| Revenue (ttm) | 211.07M |
| Net Income (ttm) | -217.11M |
| Shares Out | 111.36M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | 32.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,668,624 |
| Open | 3.31 |
| Previous Close | 3.24 |
| Day's Range | 3.14 - 3.41 |
| 52-Week Range | 1.43 - 10.99 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 10.80 (+224.32%) |
| Earnings Date | Nov 6, 2023 |
About CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the Un... [Read more]
Financial Performance
In 2022, CHRS's revenue was $211.04 million, a decrease of -35.37% compared to the previous year's $326.55 million. Losses were -$291.75 million, 1.62% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $10.8, which is an increase of 224.32% from the latest price.
News
2024 could turn into a ‘trader's market.' Here's how this strategist says you can make the most of that.
The S&P 500 index SPX has three days left this year to try for a fresh record high, which in theory, shouldn't be so hard with a Santa Rally all but teed up.
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgr...
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committ...
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemothe...
Coherus BioSciences Announces CFO Transition Plans
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the c...
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses –
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
– Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approved with launch planned for the first qu...
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –
Coherus BioSciences to Participate at Upcoming November Investor Conferences
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conference...
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market ...
Intuitive Machines stock climbs on lunar mission plan as McDonald's edges higher ahead of results
Coherus BioSciences stock CHRS, -3.65% rose 17% as the Food and Drug Administration approved its treatment for nasopharyngeal cancer when combined with chemotherapy that it makes with Shanghai Junshi ...
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemoth...
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
– Resubmission follows the satisfactory resolution of the FDA's review of inspection findings at the third-party filler –
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* – – Demonstrated safety and efficacy in clinical trials and real-world settings – – Robust and reliable supply addresses ...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipe...
Coherus BioSciences' new injector treatment for cancer patients rejected by FDA
Coherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a treatment designed to cut cancer patients' r...
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –
Coherus Completes Surface Oncology Acquisition
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment –
Coherus BioSciences to Participate at Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferenc...
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology...
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
– Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ lau...
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market clos...
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
– Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches –
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a nat...